Skip to main content
Top
Published in: Respiratory Research 1/2007

Open Access 01-12-2007 | Review

In vitro metabolism of beclomethasone dipropionate, budesonide, ciclesonide, and fluticasone propionate in human lung precision-cut tissue slices

Authors: Ruediger Nave, Robyn Fisher, Nigel McCracken

Published in: Respiratory Research | Issue 1/2007

Login to get access

Abstract

Background

The therapeutic effect of inhaled corticosteroids (ICS) may be affected by the metabolism of the drug in the target organ. We investigated the in vitro metabolism of beclomethasone dipropionate (BDP), budesonide (BUD), ciclesonide (CIC), and fluticasone propionate (FP) in human lung precision-cut tissue slices. CIC, a new generation ICS, is hydrolyzed by esterases in the upper and lower airways to its pharmacologically active metabolite desisobutyryl-ciclesonide (des-CIC).

Methods

Lung tissue slices were incubated with BDP, BUD, CIC, and FP (initial target concentration of 25 μM) for 2, 6, and 24 h. Cellular viability was assessed using adenosine 5'-triphosphate content and protein synthesis in lung slices. Metabolites and remaining parent compounds in the tissue samples were analyzed by HPLC with UV detection.

Results

BDP was hydrolyzed to the pharmacologically active metabolite beclomethasone-17-monopropionate (BMP) and, predominantly, to inactive beclomethasone (BOH). CIC was hydrolyzed initially to des-CIC with a slower rate compared to BDP. A distinctly smaller amount (approximately 10-fold less) of fatty acid esters were formed by BMP (and/or BOH) than by BUD or des-CIC. The highest relative amounts of fatty acid esters were detected for BUD. For FP, no metabolites were detected at any time point. The amount of drug-related material in lung tissue (based on initial concentrations) at 24 h was highest for CIC, followed by BUD and FP; the smallest amount was detected for BDP.

Conclusion

The in vitro metabolic pathways of the tested ICS in human lung tissue were differing. While FP was metabolically stable, the majority of BDP was converted to inactive polar metabolites. The formation of fatty acid conjugates was confirmed for BMP (and/or BOH), BUD, and des-CIC.
Literature
2.
go back to reference Georgitis JW: The 1997 Asthma Management Guidelines and therapeutic issues relating to the treatment of asthma. Chest 1999, 115:210–217.CrossRefPubMed Georgitis JW: The 1997 Asthma Management Guidelines and therapeutic issues relating to the treatment of asthma. Chest 1999, 115:210–217.CrossRefPubMed
3.
go back to reference Suissa S, Ernst P: Inhaled corticosteroids: impact on asthma morbidity and mortality. J Allergy Clin Immunol 2001, 107:937–944.CrossRefPubMed Suissa S, Ernst P: Inhaled corticosteroids: impact on asthma morbidity and mortality. J Allergy Clin Immunol 2001, 107:937–944.CrossRefPubMed
4.
go back to reference Umland SP, Schleimer RP, Johnston SL: Review of the molecular and cellular mechanisms of action of glucocorticoids for use in asthma. Pulm Pharmacol Ther 2002, 15:35–50.CrossRefPubMed Umland SP, Schleimer RP, Johnston SL: Review of the molecular and cellular mechanisms of action of glucocorticoids for use in asthma. Pulm Pharmacol Ther 2002, 15:35–50.CrossRefPubMed
5.
go back to reference Pelaia G, Vatrella A, Cuda G, Maselli R, Marsico SA: Molecular mechanisms of corticosteroid actions in chronic inflammatory airway diseases. Life Sci 2003, 72:1549–1561.CrossRefPubMed Pelaia G, Vatrella A, Cuda G, Maselli R, Marsico SA: Molecular mechanisms of corticosteroid actions in chronic inflammatory airway diseases. Life Sci 2003, 72:1549–1561.CrossRefPubMed
6.
go back to reference Derendorf H: Pharmacokinetic and pharmacodynamic properties of inhaled corticosteroids in relation to efficacy and safety. Respir Med 1997, 91:22–28.CrossRefPubMed Derendorf H: Pharmacokinetic and pharmacodynamic properties of inhaled corticosteroids in relation to efficacy and safety. Respir Med 1997, 91:22–28.CrossRefPubMed
7.
go back to reference Barnes PJ, Pedersen S, Busse WW: Efficacy and safety of inhaled corticosteroids. New developments. Am J Respir Crit Care Med 1998, 157:S1-S53.CrossRefPubMed Barnes PJ, Pedersen S, Busse WW: Efficacy and safety of inhaled corticosteroids. New developments. Am J Respir Crit Care Med 1998, 157:S1-S53.CrossRefPubMed
8.
go back to reference Lipworth BJ: Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch Intern Med 1999, 159:941–955.CrossRefPubMed Lipworth BJ: Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch Intern Med 1999, 159:941–955.CrossRefPubMed
9.
go back to reference Newman SP: Deposition and effects of inhaled corticosteroids. Clin Pharmacokinet 2003, 42:529–544.CrossRefPubMed Newman SP: Deposition and effects of inhaled corticosteroids. Clin Pharmacokinet 2003, 42:529–544.CrossRefPubMed
10.
go back to reference Rohatagi S, Appajosyula S, Derendorf H, Szefler S, Nave R, Zech K, Banerji D: Risk-benefit value of inhaled glucocorticoids: a pharmacokinetic/pharmacodynamic perspective. J Clin Pharmacol 2004, 44:37–47.CrossRefPubMed Rohatagi S, Appajosyula S, Derendorf H, Szefler S, Nave R, Zech K, Banerji D: Risk-benefit value of inhaled glucocorticoids: a pharmacokinetic/pharmacodynamic perspective. J Clin Pharmacol 2004, 44:37–47.CrossRefPubMed
11.
go back to reference Derendorf H, Nave R, Drollmann A, Cerasoli F, Wurst W: Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. Eur Respir J 2006, 28:1042–1050.CrossRefPubMed Derendorf H, Nave R, Drollmann A, Cerasoli F, Wurst W: Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. Eur Respir J 2006, 28:1042–1050.CrossRefPubMed
12.
go back to reference Dent G: Ciclesonide (Byk Gulden). Curr Opin Investig Drugs 2002, 3:78–83.PubMed Dent G: Ciclesonide (Byk Gulden). Curr Opin Investig Drugs 2002, 3:78–83.PubMed
13.
go back to reference Postma DS, Sevette C, Martinat Y, Schloesser N, Aumann J, Kafé H: Treatment of asthma by the inhaled corticosteroid ciclesonide given either in the morning or evening. Eur Respir J 2001, 17:1083–1088.CrossRefPubMed Postma DS, Sevette C, Martinat Y, Schloesser N, Aumann J, Kafé H: Treatment of asthma by the inhaled corticosteroid ciclesonide given either in the morning or evening. Eur Respir J 2001, 17:1083–1088.CrossRefPubMed
14.
go back to reference Kanniess F, Richter K, Böhme S, Jörres RA, Magnussen H: Effect of inhaled ciclesonide on airway responsiveness to inhaled AMP, the composition of induced sputum and exhaled nitric oxide in patients with mild asthma. Pulm Pharmacol Ther 2001, 14:141–147.CrossRefPubMed Kanniess F, Richter K, Böhme S, Jörres RA, Magnussen H: Effect of inhaled ciclesonide on airway responsiveness to inhaled AMP, the composition of induced sputum and exhaled nitric oxide in patients with mild asthma. Pulm Pharmacol Ther 2001, 14:141–147.CrossRefPubMed
15.
go back to reference Larsen BB, Nielsen LP, Engelstätter R, Steinijans V, Dahl R: Effect of ciclesonide on allergen challenge in subjects with bronchial asthma. Allergy 2003, 58:207–212.CrossRefPubMed Larsen BB, Nielsen LP, Engelstätter R, Steinijans V, Dahl R: Effect of ciclesonide on allergen challenge in subjects with bronchial asthma. Allergy 2003, 58:207–212.CrossRefPubMed
16.
go back to reference Nave R, Fisher R, Zech K: In Vitro metabolism of ciclesonide in human lung and liver precision-cut tissue slices. Biopharm Drug Dispos 2006, 27:197–207.CrossRefPubMed Nave R, Fisher R, Zech K: In Vitro metabolism of ciclesonide in human lung and liver precision-cut tissue slices. Biopharm Drug Dispos 2006, 27:197–207.CrossRefPubMed
17.
go back to reference Mutch E, Nave R, Zech K, Williams FM: Esterases involved in the hydrolysis of ciclesonide in human tissues. Eur Respir J 2003, 22:267s-268s. Mutch E, Nave R, Zech K, Williams FM: Esterases involved in the hydrolysis of ciclesonide in human tissues. Eur Respir J 2003, 22:267s-268s.
18.
go back to reference K D, R E, A. K: Ciclesonide: An on-site-activated steroid. In New drugs for asthma, allergy and COPD. Edited by: Hansel TT and Barnes PJ. Basel, Karger; 2001:91–93. K D, R E, A. K: Ciclesonide: An on-site-activated steroid. In New drugs for asthma, allergy and COPD. Edited by: Hansel TT and Barnes PJ. Basel, Karger; 2001:91–93.
19.
go back to reference Sato H, Nave R, Nonaka T, Mochizuki T, Takahama S, Kondo S: In vitro metabolism of ciclesonide in human nasal epithelial cells. Biopharm Drug Dispos 2007, 28:43–50.CrossRefPubMed Sato H, Nave R, Nonaka T, Mochizuki T, Takahama S, Kondo S: In vitro metabolism of ciclesonide in human nasal epithelial cells. Biopharm Drug Dispos 2007, 28:43–50.CrossRefPubMed
20.
go back to reference Nave R, Hummel RP, Wohlsen A, Herzog R, Zech K: The active metabolite of ciclesonide, des-isobutyryl ciclesonide, forms highly lipophilic fatty acid conjugates in precision-cut rat lung slices. Am J Respir Crit Care Med 2004, 169:A91. Nave R, Hummel RP, Wohlsen A, Herzog R, Zech K: The active metabolite of ciclesonide, des-isobutyryl ciclesonide, forms highly lipophilic fatty acid conjugates in precision-cut rat lung slices. Am J Respir Crit Care Med 2004, 169:A91.
21.
go back to reference Nave R, Meyer W, Fuhst R, Zech K: Formation of fatty acid conjugates of ciclesonide active metabolite in the rat lung after 4-week inhalation of ciclesonide. Pulm Pharmacol Ther 2005, 18:390–396.CrossRefPubMed Nave R, Meyer W, Fuhst R, Zech K: Formation of fatty acid conjugates of ciclesonide active metabolite in the rat lung after 4-week inhalation of ciclesonide. Pulm Pharmacol Ther 2005, 18:390–396.CrossRefPubMed
22.
go back to reference Miller-Larsson A, Mattsson H, Hjertberg E, Dahlbäck M, Tunek A, Brattsand R: Reversible fatty acid conjugation of budesonide. Novel mechanism for prolonged retention of topically applied steroid in airway tissue. Drug Metab Dispos 1998, 26:623–630.PubMed Miller-Larsson A, Mattsson H, Hjertberg E, Dahlbäck M, Tunek A, Brattsand R: Reversible fatty acid conjugation of budesonide. Novel mechanism for prolonged retention of topically applied steroid in airway tissue. Drug Metab Dispos 1998, 26:623–630.PubMed
23.
go back to reference Tunek A, Sjödin K, Hallström G: Reversible formation of fatty acid esters of budesonide, an antiasthma glucocorticoid, in human lung and liver microsomes. Drug Metab Dispos 1997, 25:1311–1317.PubMed Tunek A, Sjödin K, Hallström G: Reversible formation of fatty acid esters of budesonide, an antiasthma glucocorticoid, in human lung and liver microsomes. Drug Metab Dispos 1997, 25:1311–1317.PubMed
24.
go back to reference Würthwein G, Rohdewald P: Activation of beclomethasone dipropionate by hydrolysis to beclomethasone-17-monopropionate. Biopharm Drug Dispos 1990, 11:381–394.CrossRefPubMed Würthwein G, Rohdewald P: Activation of beclomethasone dipropionate by hydrolysis to beclomethasone-17-monopropionate. Biopharm Drug Dispos 1990, 11:381–394.CrossRefPubMed
25.
go back to reference Fisher RL, Gandolfi AJ, Brendel K: Human liver quality is a dominant factor in the outcome of in vitro studies. Cell Biol Toxicol 2001, 17:179–189.CrossRefPubMed Fisher RL, Gandolfi AJ, Brendel K: Human liver quality is a dominant factor in the outcome of in vitro studies. Cell Biol Toxicol 2001, 17:179–189.CrossRefPubMed
26.
go back to reference Fisher RL, Smith MS, Hasal SJ, Hasal KS, Gandolfi AJ, Brendel K: The use of human lung slices in toxicology. Hum Exp Toxicol 1994, 13:466–471.CrossRefPubMed Fisher RL, Smith MS, Hasal SJ, Hasal KS, Gandolfi AJ, Brendel K: The use of human lung slices in toxicology. Hum Exp Toxicol 1994, 13:466–471.CrossRefPubMed
27.
go back to reference Kricka LJ: Clinical and biochemical applications of luciferases and luciferins. Anal Biochem 1988, 175:14–21.CrossRefPubMed Kricka LJ: Clinical and biochemical applications of luciferases and luciferins. Anal Biochem 1988, 175:14–21.CrossRefPubMed
28.
go back to reference Nave R, Gunawardena KA, Zech K, Bethke TD: Pharmacokinetic disposition of inhaled ciclesonide and its metabolite desisobutyryl-ciclesonide in healthy subjects and patients with asthma are similar. Int J Clin Pharmacol Ther 2006, 44:1–7.CrossRefPubMed Nave R, Gunawardena KA, Zech K, Bethke TD: Pharmacokinetic disposition of inhaled ciclesonide and its metabolite desisobutyryl-ciclesonide in healthy subjects and patients with asthma are similar. Int J Clin Pharmacol Ther 2006, 44:1–7.CrossRefPubMed
29.
go back to reference Mackie AE, McDowall JE, Falcoz C, Ventresca P, Bye A, Daley-Yates PT: Pharmacokinetics of Fluticasone Propionate inhaled via the Diskhaler® and Diskus® Powder Devices in Healthy Volunteers. Clin Pharmacokinet 2000, 39:23–30.CrossRefPubMed Mackie AE, McDowall JE, Falcoz C, Ventresca P, Bye A, Daley-Yates PT: Pharmacokinetics of Fluticasone Propionate inhaled via the Diskhaler® and Diskus® Powder Devices in Healthy Volunteers. Clin Pharmacokinet 2000, 39:23–30.CrossRefPubMed
30.
go back to reference Van Den Bosch JMM, Westermann CJJ, Aumann J, Edsbäcker S, Tönnesson M, Selroos O: Relationship between lung tissue and blood plasma concentrations of inhaled budesonide. Biopharmaceutics and Drug Disposition 1993, 14:455–459.CrossRefPubMed Van Den Bosch JMM, Westermann CJJ, Aumann J, Edsbäcker S, Tönnesson M, Selroos O: Relationship between lung tissue and blood plasma concentrations of inhaled budesonide. Biopharmaceutics and Drug Disposition 1993, 14:455–459.CrossRefPubMed
31.
go back to reference Esmailpour N, Högger P, Rabe KF, Heitmann U, Nakashima M, Rohdewald P: Distribution of inhaled fluticasone propionate between human lung tissue and serum in vivo. Eur Respir J 1997, 10:1496–1499.CrossRefPubMed Esmailpour N, Högger P, Rabe KF, Heitmann U, Nakashima M, Rohdewald P: Distribution of inhaled fluticasone propionate between human lung tissue and serum in vivo. Eur Respir J 1997, 10:1496–1499.CrossRefPubMed
32.
go back to reference Nonaka T, Nave R, McCracken N, Kawashimo A, Katsuura Y: Ciclesonide uptake and metabolism in human alveolar type II epithelial cells (A549). BMC Pharmacol 2007,7(1):12.CrossRefPubMedPubMedCentral Nonaka T, Nave R, McCracken N, Kawashimo A, Katsuura Y: Ciclesonide uptake and metabolism in human alveolar type II epithelial cells (A549). BMC Pharmacol 2007,7(1):12.CrossRefPubMedPubMedCentral
33.
go back to reference Holz O, Zühlke I, Einhaus M, Welker L, Kanniess F, Branscheid D, Nakashima M, Harrison LI, Jörres RA, Richter K, Magnussen H: Direct measurement of BDP and 17-BMP in bronchial and peripheral lung tissue after inhalation of HFA- vs CFC-driven aerosols. Pulmonary Pharmacology and Therapeutics 2004, 17:233–238.CrossRefPubMed Holz O, Zühlke I, Einhaus M, Welker L, Kanniess F, Branscheid D, Nakashima M, Harrison LI, Jörres RA, Richter K, Magnussen H: Direct measurement of BDP and 17-BMP in bronchial and peripheral lung tissue after inhalation of HFA- vs CFC-driven aerosols. Pulmonary Pharmacology and Therapeutics 2004, 17:233–238.CrossRefPubMed
34.
go back to reference Nave R, Zech K, Bethke TD: Lower oropharyngeal deposition of inhaled ciclesonide via hydrofluoroalkane metered-dose inhaler compared with budesonide via chlorofluorocarbon metered-dose inhaler in healthy subjects. Eur J Clin Pharmacol 2005, 61:203–208.CrossRefPubMed Nave R, Zech K, Bethke TD: Lower oropharyngeal deposition of inhaled ciclesonide via hydrofluoroalkane metered-dose inhaler compared with budesonide via chlorofluorocarbon metered-dose inhaler in healthy subjects. Eur J Clin Pharmacol 2005, 61:203–208.CrossRefPubMed
35.
go back to reference Richter K, Kanniess F, Biberger C, Nave R, Magnussen H: Comparison of the oropharyngeal deposition of inhaled ciclesonide and fluticasone propionate in patients with asthma. J Clin Pharmacol 2005, 45:146–152.CrossRefPubMed Richter K, Kanniess F, Biberger C, Nave R, Magnussen H: Comparison of the oropharyngeal deposition of inhaled ciclesonide and fluticasone propionate in patients with asthma. J Clin Pharmacol 2005, 45:146–152.CrossRefPubMed
36.
go back to reference Engelstätter R, Escher A, Haefner D: Low incidence of oropharyngeal adverse events in asthma patients treated with ciclesonide. Eur Respir J 2005, 26:255s. Engelstätter R, Escher A, Haefner D: Low incidence of oropharyngeal adverse events in asthma patients treated with ciclesonide. Eur Respir J 2005, 26:255s.
37.
go back to reference Chapman KR, Patel P, D'Urzo AD, Alexander M, Mehra S, Oedekoven C, Engelstätter R, Boulet LP: Maintenance of asthma control by once-daily inhaled ciclesonide in adults with persistent asthma. Allergy 2005, 60:330–337.CrossRefPubMed Chapman KR, Patel P, D'Urzo AD, Alexander M, Mehra S, Oedekoven C, Engelstätter R, Boulet LP: Maintenance of asthma control by once-daily inhaled ciclesonide in adults with persistent asthma. Allergy 2005, 60:330–337.CrossRefPubMed
38.
go back to reference Mintz S, Alexander M, Li JH, Mayer PV: Once-daily administration of budesonide Turbuhaler was as effective as twice-daily treatment in patients with mild to moderate persistent asthma. J Asthma 2002, 39:203–210.CrossRefPubMed Mintz S, Alexander M, Li JH, Mayer PV: Once-daily administration of budesonide Turbuhaler was as effective as twice-daily treatment in patients with mild to moderate persistent asthma. J Asthma 2002, 39:203–210.CrossRefPubMed
Metadata
Title
In vitro metabolism of beclomethasone dipropionate, budesonide, ciclesonide, and fluticasone propionate in human lung precision-cut tissue slices
Authors
Ruediger Nave
Robyn Fisher
Nigel McCracken
Publication date
01-12-2007
Publisher
BioMed Central
Published in
Respiratory Research / Issue 1/2007
Electronic ISSN: 1465-993X
DOI
https://doi.org/10.1186/1465-9921-8-65

Other articles of this Issue 1/2007

Respiratory Research 1/2007 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.